|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| ALREKKFsTKSDVWS SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 448477 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Putative in vivo kinases: | |
| Kinases, in vitro: | |
| Treatments: | |
| Downstream Regulation | |
|---|---|
| Effects of modification on CSK: | |
| Induce interaction with: | |
| References | |
|---|---|
|
Cui N, et al. (2019) SUMOylation of Csk Negatively Modulates its Tumor Suppressor Function. Neoplasia 21, 676-688
31125786 Curated Info |
|
|
Kim MS, et al. (2018) Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget 9, 5979-5992
29464048 Curated Info |
|
|
Smida M, et al. (2007) A novel negative regulatory function of the phosphoprotein associated with glycosphingolipid-enriched microdomains: blocking Ras activation. Blood 110, 596-615
17389760 Curated Info |
|
|
Yaqub S, et al. (2003) Activation of C-terminal Src kinase (Csk) by phosphorylation at serine-364 depends on the Csk-Src homology 3 domain. Biochem J 372, 271-8
12600271 Curated Info |
|
|
Vang T, et al. (2001) Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193, 497-507
11181701 Curated Info |
